Adimab Initiates Update on Clinical Progression of Partner Programs
- Six New Partner Programs Entered the Clinic in 2017 -
- Total of Nine Partner Programs Currently in Clinical Trials -
LEBANON, N.H.--(BUSINESS WIRE)-- Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that six new partner programs entered clinical trials in 2017. This brings the total number of Adimab partner programs currently in clinical development to nine.
“Over the past eight years our partners have initiated more than 200 therapeutic discovery programs, and the earliest of those programs are now starting to enter the clinic,” noted Guy Van Meter, Senior Vice President of Business Development at Adimab.
Currently, Innovent Biologics is in Phase III clinical trials, which is the most advanced partner program based on the Adimab technology. In addition, Arsanis entered Phase II clinical trials with two Adimab antibodies. Six other Adimab partners initiated Phase I clinical trials in 2017, including Mersana, Checkpoint Therapeutics, and Kite Pharma (now a wholly owned subsidiary of Gilead Sciences).
In 2017, Adimab partners exercised options to 15 commercial licenses to advance programs into preclinical development. These partners include Biogen, Celgene, Surface Oncology, The University of Texas MD Anderson Cancer Center, and others.
“We have invested heavily in becoming the premier provider of antibody discovery technology,” commented Tillman Gerngross, Ph.D., Chief Executive Officer and Co-Founder of Adimab. “As a platform company, we are not pursuing our own drug pipeline but have instead focused on the success of our partners. As such, we are thrilled to see the maturation of their programs and the early clinical impact of our work. Based on the number of option exercises to date we expect to see significant growth in the number of clinical trials over the next few years.”
Over the past eight years Adimab has partnered with over 50 pharmaceutical and biotechnology companies. The Adimab technology has been transferred and implemented at Merck, Novo Nordisk, Biogen, GSK and Lilly. Funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many early-stage venture-backed companies, including Innovent, Alector, Surface Oncology, Potenza and others, as well as mid-size public biopharmaceutical companies such as Kite, Merrimack, Mersana, Five Prime, Jounce, Acceleron, and Arsanis.
Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.
Guy Van Meter, 603-653-5775
SVP of Business Development
Source: Adimab, LLC